Consensus Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Market Closed - Nyse 04:00:01 2024-04-23 pm EDT 5-day change 1st Jan Change
285.3 USD +1.84% Intraday chart for Bio-Rad Laboratories, Inc. -2.55% -11.65%

Evolution of the average Target Price on Bio-Rad Laboratories, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ba74a90aba6efba4af86632cbcbf38c.Hrd2bZB38cmBfPGYu9VH2V2Go5XK4cNw2gWgjLuXU70.W9xPPqUHh_HbKpOt5LoM6hTuyvC6i5khgET_w8P1IvBvhT0uqU_Bi_hJsA~67888a3e8997864e237fe70cfa5d59b4
Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT
RBC Trims Price Target on Bio-Rad Laboratories to $474 From $480, Keeps Outperform Rating MT
Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $365 From $400 MT
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating MT
RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating MT
Analyst recommendations: Blackstone, Citigroup, Icon, Amazon, Broadcom... Our Logo
UBS Initiates Coverage on Bio-Rad Laboratories With Buy Rating, $395 Price Target MT
RBC Cuts Price Target on Bio-Rad Laboratories to $482 From $513, Notes 'Near-Term Headwinds,' Keeps Outperform Rating MT
ANALYST RECOMMENDATIONS : Amazon, Comcast, Intel, Merck, Roblox... Our Logo
Wells Fargo Adjusts Price Target on Bio-Rad Laboratories to $525 From $550, Keeps Overweight Rating MT
Wells Fargo Lowers Price Target on Bio-Rad Laboratories to $525 From $550, Maintains Overweight Rating MT
Credit Suisse Adjusts Bio-Rad Laboratories' Price Target to $550 From $580, Keeps Outperform Rating MT
RBC Raises Price Target on Bio-Rad Laboratories to $524 From $522, Maintains Outperform Rating MT
RBC Cuts Bio-Rad Laboratories' Price Target to $522 From $536, Keeps Outperform Rating MT
Wells Fargo Initiates Bio-Rad Laboratories With Overweight Rating, $550 Price Target MT
ANALYST RECOMMENDATIONS : Adobe, Wells Fargo, American Express... Our Logo
RBC Boosts Price Target on Bio-Rad Laboratories to $536 From $531, Maintains Outperform Rating MT
Citigroup Adjusts Bio-Rad Laboratories' Price Target to $525 From $550, Keeps Buy Rating MT
RBC Cuts Price Target on Bio-Rad Laboratories to $531 From $582 After Guidance Cut But Sees Buying Opportunity After Stock Drop; Outperform Kept MT
Credit Suisse Cuts Bio-Rad Laboratories' PT to $580 From $680 After Lower-Than-Expected Q1 Results, Keeps Outperform Rating MT
RBC Boosts Price Target on Bio-Rad Laboratories to $582 From $579, Maintains Outperform Rating MT
RBC Raises Price Target on Bio-Rad Laboratories to $582 From $579, Maintains Outperform Rating MT
Credit Suisse Adjusts Price Target on Bio-Rad Laboratories to $680 From $640, Maintains Outperform Rating MT
RBC Lifts Price Target on Bio-Rad Laboratories to $579 From $571, Says 'Strong' Results, Outlook 'Not Reflected in Shares,' Keeps Outperform Rating MT
RBC Boosts Price Target on Bio-Rad Laboratories to $571 From $565, Maintains Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
285.3 USD
Average target price
428.9 USD
Spread / Average Target
+50.34%
High Price Target
474 USD
Spread / Highest target
+66.15%
Low Price Target
365 USD
Spread / Lowest Target
+27.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bio-Rad Laboratories, Inc.

Zacks Investment Research
RBC Capital Markets
Citigroup
UBS
Wells Fargo Securities
Credit Suisse
B. Riley
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. Consensus Bio-Rad Laboratories, Inc.